Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT [0.03%]
Michael Braun,Oleg Gluz,Sherko Kuemmel et al.
Michael Braun et al.
Introduction: In HR+/HER2- high-risk early breast cancer (eBC), the NATALEE and monarchE trials demonstrated improved survival after the addition of CDK4/6 inhibitors to endocrine treatment (ET). However, the absolute ben...
Validity and Reliability Study of the Turkish Version of the Breast Cancer Stigma Scale: A Methodological Study [0.03%]
土耳其乳腺癌耻辱量表版本的有效性和可靠性研究：一种方法学研究
Nurten Şişman,Zeynep Erdogan
Nurten Şişman
Introduction: The purpose of this methodological and descriptive study was to conduct the validity and reliability study of the Breast Cancer Stigma Scale (BCSS) for the Turkish population of breast cancer patients. ...
Mastalgia, Radiological Yield, and Psychological Burden: A Cross-Sectional Comparative Study [0.03%]
乳房疼痛的放射学阳性率和心理负担：横断面比较研究
Seda Aladag Kurt,Irem Hacisalihoglu Aydin,Busra Ucar Bostan et al.
Seda Aladag Kurt et al.
Introduction: The aim of this study was to investigate the clinical, radiological, and psychological correlates of mastalgia and to determine the factors independently associated with anxiety and depression in women prese...
Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives [0.03%]
早期激素受体阳性、人类表皮生长因子受体阴性乳腺癌的治疗体验——欧洲患者的观点
Maggie Banys-Paluchowski,Diana Lüftner,Agnieszka Korfel et al.
Maggie Banys-Paluchowski et al.
Introduction: This study evaluated the experiences of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer (EBC) in France, Germany, Italy, Spain, and the UK...
Surgical Outcome Parameters in Breast Cancer: A Survey Comparing Oncoplastic and Non-Oncoplastic Surgeons as well as Certified with Non-Certified Breast Health Centers [0.03%]
乳腺癌外科治疗效果参数的调查研究：对比肿瘤整形与非肿瘤整形外科医生以及认证与非认证乳腺诊疗中心
Kerstin Wimmer,Kathia Gordon,Klaus Emmanuel et al.
Kerstin Wimmer et al.
Introduction: Breast cancer surgery has evolved over the past few decades, with an increase in the number of oncoplastic surgeons and certified breast centers worldwide. However, it remains unclear whether this has led to...
Prevention of Severe Postoperative Pain after Breast Surgery Using Opioid-Sparing Analgesia with Intraoperative and Drain-Based Ropivacaine Infiltration: A Prospective Observational Study [0.03%]
预防乳腺手术后重度术后疼痛的 opioid-sparing 治疗：围术期和引流管基质下使用罗哌卡因的观察性研究
Jorge Jiménez Cruz,Norah L A Emrich,Kristin Nicolaus-Tellenbach et al.
Jorge Jiménez Cruz et al.
Background and aim: Breast surgery is frequently associated with high postoperative pain, which if not adequately managed can delay recovery and increase the risk of chronic postsurgical pain. This study evaluated whether...
Rachel Wuerstlein,Eva Schumacher-Wulf,Volkmar Müller et al.
Rachel Wuerstlein et al.
Nina Ditsch,Michael Untch,Peter A Fasching et al.
Nina Ditsch et al.
Background: The "International Consensus Conference for Advanced Breast Cancer" was initiated with the rationale to standardize treatment of advanced breast cancer (ABC) based on available evidence. The aim was to ensure ...
Postoperative Chylous Leakage in Breast Cancer Patients: A Multicentre Case Series [0.03%]
乳腺癌术后患者出现乳糜漏的多中心病例系列研究
Billy Ho Hung Cheung,Ka Yan Theresa Tse,Sara Wing Yung Li et al.
Billy Ho Hung Cheung et al.
Introduction: Chylous leakage is a rare complication following breast cancer surgery, characterized by milky, lipid-rich fluid collection in surgical drains. While well documented in thoracic and abdominal surgeries, its ...
Comparison of Prosigna® Assay and Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Results in Early-Stage Breast Cancer Patients [0.03%]
Prosigna®和尿激酶型纤溶酶原激活剂/纤溶酶原激活剂抑制物-1在早期乳腺癌患者中的对比研究
Laura Rickerl,Harald Bartsch,Nadia Harbeck et al.
Laura Rickerl et al.
Background: The decision-making process regarding adjuvant treatment in estrogen receptor-positive (ER+), HER2-negative early-stage breast cancer (EBC) is often not sufficient, when based on established clinicopathologica...